When it comes to patients with lung cancer, tumor mutation burden (TMB) may be the answer, according to recent research presented at the 2019 ASCO Annual Meeting. The Inflammation-Depression Connection Clinicians measured patients’ TMB to determine if they are likely to respond to immunotherapy ...
These include expression of PD-L1 and defects in DNA mismatch repair (MMR).Tumor mutation burden (TMB) has been associated with response to immune checkpoint inhibitors. The current investigation examines TMB as a biomarker of response to immunotherapy in breast cancer.Publicly available data from ...
University of Texas M. D. Anderson Cancer Center Credit: CC0 Public Domain A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types, according to a...
Tumor-specific mutations can result in immunogenic neoantigens, both of which have been correlated with responsiveness to immune checkpoint inhibitors in highly mutagenic cancers. However, early results of single-agent checkpoint inhibitors in multiple myeloma (MM) have been underwhelming. Therefore, we ...
Atezolizumab Plus Bevacizumab as First-Line Treatment for Patients With Metastatic Nonsquamous NSCLC With High Tumor Mutation Burden JAMA Oncology Save Recommend Share Sign in to PracticeUpdate Only registered members have full access to Pra...
The tumor mutational burden (TMB) and intratumoral heterogeneity (ITH) of the platinum-resistant group were significantly higher than those of the platinum-sensitive group (P=0.0321 and P=0.0452, respectively). TMB, neoantigen and ITH had certain predictive value according to the area under the re...
Although there was no difference in survival rate based on the tumor mutation burden, we speculated that BCs with high mutation rates would possess aggressive clinical features. High mutation rate was found to be more frequent in patients with age ≥50 compared to patients with age <50 (p ...
Tumor burden as measured by radiance emitted from the luciferase-HL60 cells declined to background levels indicating clearance of the tumor cells, whereas the IgG control treated mice, the radiance increased, reflecting increased tumor growth. This result was comparable to that observed with the hu...
For the spatial and temporal analyses of cancer panel data, we performed mutation calling with MuTect51 using the P0 (the first stable xenograft after implantation from the patient tumor fragment) as control. MuTect using the vehicle as control gave very similar results (data not shown). For ...
Biomarker discovery will also be focused on the fallopian tube to identify better approaches for early detection and these data augment the scientific underpinning for reducing the burden of ovarian cancer. Methods Patients and tumor samples We reviewed the records of all women diagnosed with HGSC of...